



UK Office

Everest Biotech Ltd

Cherwell Innovation Centre
77 Heyford Park
Upper Heyford
Oxfordshire
OX25 5HD
UK

Enquiries:

info@everestbiotech.com

Sales:

sales@everestbiotech.com

Tech support:

support@everestbiotech.com

Tel: +44 (0)1869 238326

www.everestbiotech.com

**Research Use Only. Not for
diagnostic or therapeutic use.**

EB06550 - Goat Anti-LRRK2 / PARK8 (near C Terminus) Antibody

Size: 100µg specific antibody in 200µl



Target Protein

Principal Names: LRRK2, PARK8, ROCO2, FLJ45829, DKFZp434H2111, leucine-rich repeat kinase 2, dardarin, Parkinson disease (autosomal dominant) 8

Official Symbol: LRRK2

Accession Number(s): NP_940980.3

Human GeneID(s): [120892](#)

Immunogen

Peptide with sequence CELAEKMRRTSV, from the internal region (near the C Terminus) of the protein sequence according to NP_940980.3.

Please note the [peptide](#) is available for sale.

Purification and Storage

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

Aliquot and store at -20°C. Minimize freezing and thawing.

Applications Tested

Peptide ELISA: antibody detection limit dilution 1:128000.

Immunofluorescence: Strong expression of the protein seen in the vesicles of A431 cells and in the vesicles and nuclei of A549 cells. Recommended concentration: 10µg/ml.

Species Reactivity

Tested: Human

Expected from sequence similarity: Human

Specific References

This antibody has been successfully used in the following paper:

Adrien De Guilhem De Lataillade, Martial Caillaud, Thibault Oullier, Philippe Naveilhan, Carolina Pellegrini, Eduardo Tolosa, Michel Neunlist, Malvyne Rolli-Derkinderen, Ellen Gelpi, Pascal Derkinderen

LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines.

J Neurochem. 2023 Jan;164(2):193-209.

PMID: 36219522

This antibody (previous batch) has been successfully used in ICC on Human:

Sharma S, Bandopadhyay R, Lashley T, Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilariño-Güell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL.

LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: A morphological and quantitative study.

Neuropathol Appl Neurobiol. 2011 Jun 23.

PMID: 21696411

This antibody (previous batch) has been successfully used in IEM:

Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R.

LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.

Hum Mol Genet. 2009 Nov 1;18(21):4022-34.

PMID: 19640926

This antibody (previous batch) has been successfully used in WB and IHC on Human:

Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R.

LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.

Neuropathol Appl Neurobiol. 2007 Oct 26.

PMID: 17971075

EB06550 Immunofluorescence analysis of paraformaldehyde fixed A431 cells, permeabilized with 0.15% Triton.

Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing vesicle staining. The nuclear stain is DAPI (blue).

Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).

EB06550 Immunofluorescence analysis of paraformaldehyde fixed A549 cells, permeabilized with 0.15% Triton.

Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing nuclear and vesicle staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).